

Remarks

In view of the above amendments and the following remarks, it is submitted that the objections raised in the Notice of Drawing Inconsistency with Specification have been obviated.

Support for these amendments is found in Figures 13A-C themselves. In particular, these figures collectively show the two alternative formats for oligonucleotide probe capture. Figure 13B shows the first format where alleles are distinguished by the presence of fluorescent signal F1 at either address Z1 or address Z2. Alternatively, Figure 13C shows the format where alleles are all detected at address Z1 but are distinguished based on whether fluorescent signal F1 or fluorescent signal F2 is emitted. How the different oligonucleotide probes for each format are configured for hybridization to a target sequence and ligation to one another is shown in Figure 13A.

In view of the above amendments, it is submitted that this case is in condition for examination.

Respectfully submitted,

Date: December 1, 2005



Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1304
Facsimile: (585) 263-1600


CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) _____.

December 1, 2005
Date


Signature

Wendy L. Barry
Type or Print Name